Get the Stockscreener App
22.44
1.54%
0.34
Precipio Inc stock is traded at $22.44, with a volume of 13,104.
It is up +1.54% in the last 24 hours and down -13.82% over the past month.
Precipio Inc is a healthcare biotechnology company focused on cancer diagnostics. Its objective is to enhance diagnostic accuracy & accessibility while building a sustainable business model that supports ongoing innovation. The company operates Clinical Laboratory Improvement Amendments laboratories in both New Haven, Connecticut, & Omaha, Nebraska, providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. The company operates in a single segment, which includes two divisions: the Pathology Services Division & the Products Division. The Pathology Services provides specialized cancer diagnostic testing services. The pathology services division specializes in diagnostic testing focused mainly on hematologic cancers.
See More
Previous Close:
$22.10
Open:
$21.88
24h Volume:
13,104
Relative Volume:
0.40
Market Cap:
$40.11M
Revenue:
$24.05M
Net Income/Loss:
$-363.00K
P/E Ratio:
-76.09
EPS:
-0.2949
Net Cash Flow:
$359.00K
1W Performance:
-2.43%
1M Performance:
-13.82%
6M Performance:
-6.73%
1Y Performance:
+106.82%
1-Day Range:
$21.80
$22.95
1-Week Range:
$21.80
$24.30
52-Week Range:
$10.50
$33.63
Precipio Inc Stock (PRPO) Company Profile
Name
Precipio Inc
Sector
Industry
Phone
203 787 7888
Address
4 SCIENCE PARK, NEW HAVEN, CT
Compare PRPO vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRPO
Precipio Inc
|
22.44 | 40.11M | 24.05M | -363.00K | 359.00K | -0.2949 |
TMO
Thermo Fisher Scientific Inc
|
473.72 | 176.04B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
181.10 | 128.18B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
570.00 | 44.96B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
130.59 | 36.88B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
357.76 | 35.13B | 3.77B | 449.25M | 240.68M | 7.8556 |
Precipio Inc Stock (PRPO) Latest News
Precipio (PRPO) AGM 2026 Summary - Quartr
Precipio Shareholders Back Board Nominees and Auditor - TipRanks
[8-K] Precipio, Inc. Reports Material Event - Stock Titan
Precipio to Present at the Planet MicroCap Las Vegas - Weekly Voice
Precipio Inc Annual Shareholders Meeting Transcript - GuruFocus
Precipio Inc. (PRPO) Q2 2025 Earnings: Positive EPS Achieved Amid Stock DeclineEBITDA Analysis - newsline.com
Precipio urges shareholders to vote ahead of Saturday meeting - Investing.com
Precipio urges shareholders to vote ahead of Saturday meeting By Investing.com - Investing.com Australia
Precipio is requesting Shareholders/Brokers vote today to avoid costly adjournment and rescheduling of Annual Shareholders Meeting - The Manila Times
Lack of quorum may force costly delay of Precipio shareholder meeting - Stock Titan
Cancer diagnostics firm Precipio heads to Vegas for Planet MicroCap 2026 - Stock Titan
Avoiding Lag: Real-Time Signals in (PRPO) Movement - Stock Traders Daily
Precipio Inc. (PRPO) Edges Higher Amid Consolidation Near ResistanceShort Setup Alerts - newsline.com
Precipio Inc. (PRPO) Edges Higher as Stock Nears ResistanceSell Signal Alerts - newsline.com
Precipio (PRPO) Q1 2026 Earnings Call Transcript - AOL.com
Precipio Q2 2025 Earnings: Positive EPS Marks a Milestone Despite Market ReactionMargin Compression Risk - newsline.com
Precipio (PRPO) Q4 2025 Earnings Transcript - AOL.com
Discipline and Rules-Based Execution in PRPO Response - Stock Traders Daily
PRPO Q2 2025 Earnings: Positive EPS Marks a Turning Point for Diagnostic PlatformEarnings Growth Forecast - The Legal Advocate
Precipio director Richard Sandberg sells $22,517 in common stock By Investing.com - Investing.com Nigeria
Precipio director Richard Sandberg sells $22,517 in common stock - Investing.com
Precipio (PRPO) director-linked entity reports 900-share open-market sale - Stock Titan
Number of shareholders of Precipio, Inc. – GETTEX:TGK - TradingView
Precipio Q2 2025 Earnings: Company Reports Positive EPS of $0.05; Stock Declines 3.09%Earnings Quality Score - newsline.com
Precipio Inc. (PRPO) Q2 2025 Earnings: Unexpected Profitability Amid Revenue ChallengesRetail Earnings Report - newsline.com
Precipio Stock Slides Before Holiday — Why Tuesday’s Open Matters - Bez Kabli
Precipio Stock Slips Post Q1 Earnings Despite Revenue Growth - TradingView
Precipio (PRPO) director Sandberg reports 3,134-share net stock sale in Form 4 - Stock Titan
Precipio Inc (PRPO) Q1 2026 Earnings Call Highlights: Revenue Growth Amidst Margin Challenges By GuruFocus - Investing.com Canada
Precipio Inc (PRPO) Q1 2026 Earnings Call Highlights: Revenue Gr - GuruFocus
Earnings call transcript: Precipio Inc Q1 2026 sees revenue growth amid margin pressures - Investing.com Nigeria
Insider sales at PRPO (NASDAQ: PRPO) list 500, 101 and 1,399-share trades - Stock Titan
Q1 2026 Precipio Inc Earnings Call Transcript - GuruFocus
Behavioral Patterns of PRPO and Institutional Flows - Stock Traders Daily
Precipio stock (US74019G1040): cancer diagnostics specialist reports recent financing moves and busi - AD HOC NEWS
Precipio, Inc.Common Stock (NQ: PRPO - The Chronicle-Journal
Precipio stock (US74019G1040): cancer diagnostics specialist in focus after recent financing update - AD HOC NEWS
Precipio (PRPO) Reports Q2 2025 Results — EPS $0.05 Meets ConsensusMost Discussed Stocks - Newser
Precipio (PRPO) CEO Highlights Growth Prospects Amid Flat Revenue - GuruFocus
Precipio Q1 revenue rises on higher pathology sales - TradingView
Precipio Announces Q1 2026 Financial Results - The Manila Times
Precipio Q1 2026 Earnings Call Transcript - MarketBeat
Surging revenue but going-concern risk for Precipio (NASDAQ: PRPO) in Q1 2026 - Stock Titan
Precipio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Management team’s 2025 market-based Options have vested - The Manila Times
Precipio Inc Stock (PRPO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.43%
2.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):